Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients

Glucagon-like peptide-1 receptor agonists are increasingly prescribed to reproductive-aged patients, yet pharmacovigilance data on menstrual outcomes remain sparse. Using the FDA Adverse Event Reporting System data through March 2026, we performed disproportionality and Bayesian analyses restricted to female patients aged 12-55 years in a retrospective cohort study. Semaglutide demonstrated the broadest signal profile, with disproportionate reporting of heavy menstrual bleeding, intermenstrual bleeding, menstrual clots, oligomenorrhea, and anovulatory cycles. Tirzepatide generated signals for intermenstrual bleeding and menstrual clots. Liraglutide produced no significant signals. These findings suggest pleiotropic effects on menstrual physiology and may support inclusion of menstrual health in counseling for reproductive-aged patients.